^
Association details:
| Biomarker: | MSH6 rs3136228 |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MSH3 and MSH6 gene polymorphisms: Association with lung cancer susceptibility and prognostic value in patients with NSCLC undergoing platinum-based chemotherapy.
Published date:
05/25/2023
Excerpt:
In this cohort study, we evaluated the association of MSH3 (rs26279) and MSH6 (rs3136228) SNPs with occurrence of lung cancer (LC), baseline demographic and clinical characteristics and with overall survival (OS) amongst LC patients undergoing platinum-based doublet chemotherapy....Patients treated with docetaxel-platinum chemotherapy and carrying heterozygous (GT) genotype for MSH6 polymorphism had worse OS (median 4.9 vs 9.1 months; adjusted HR = 2.3; p = 0.03).
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.16_suppl.9031
